MODAGIN
LIVE

Serial Number

97828693

Owner

MODAG GmbH

Attorney

Ralph G. Fischer

Filing Date

Mar 8, 2023

Add to watchlist:

No watchlists yet
View on USPTO

MODAGIN Trademark

Serial Number: 97828693 • Registration: 7617828

MODAGIN is a trademark filed by MODAG GmbH on March 8, 2023. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently registered and active.

Owner Contact Info

MODAG GmbH (3 trademarks)

Mikroforum Ring 3
Wendelsheim 55234 , DE

Entity Type: 99

Trademark Details

Filing Date

March 8, 2023

Registration Date

December 24, 2024

Published for Opposition

October 22, 2024

Goods & Services

Medication counseling; Providing information to patients in the field of administering medications; Providing medical information relating to pharmaceutical products; Providing information relating to the treatment of degenerative diseases; Providing information relating to medical services; Medical advisory services relating to degenerative diseases; Medical consultancy and medical information services relating to pharmaceutical products; Medical consultancy and medical information services relating to pharmaceutical products provided via the Internet; Medical consultancy and medical information services relating to medical products; Medical consultancy services relating to medicines; Medical services; Medical services for the treatment of Alzheimer's disease; Pharmaceutical compounding services; Preparation and administration of medicines being medical services

Medicines for human medical purposes in the nature of pharmaceutical preparations for the use in the treatment of neurodegenerative diseases, Alzheimer's disease, cardiovascular and cerebrovascular diseases, central nervous system, Parkinson's disease; Medicines for veterinary purposes for treatment of neurodegenerative diseases, Alzheimer's disease, cardiovascular and cerebrovascular diseases, central nervous system, Parkinson's disease; Pharmaceuticals and natural remedies, namely, natural remedy preparations for the treatment of neurodegenerative diseases, Alzheimer's disease, cardiovascular and cerebrovascular diseases, central nervous system, Parkinson's disease; Medicines for the treatment of Alzheimer's disease; Medicines for the treatment of neurodegenerative diseases; Medicines for the treatment of cardiovascular and cerebrovascular diseases; Chemical-pharmaceutical preparations for the treatment of neurodegenerative diseases, Alzheimer's disease, cardiovascular and cerebrovascular diseases, central nervous system, Parkinson's disease; Chemical reagents for medical or veterinary purposes; Diagnostic preparations for medical or veterinary purposes; Diagnostic preparations and materials for medical purposes; Diagnostic biomarker reagents for medical purposes; Diagnostic reagents for medical purposes; Injectable pharmaceuticals for the treatment of neurodegenerative diseases, Alzheimer's disease, cardiovascular and cerebrovascular diseases, central nervous system, Parkinson's disease; Medicinal preparations and substances for the treatment of neurodegenerative diseases, Alzheimer's disease, cardiovascular and cerebrovascular diseases, central nervous system, Parkinson's disease; Agents against Parkinson's disease, namely, pharmaceutical agents for the treatment of Parkinson's disease; Pharmaceutical medicines in the nature of pharmaceutical preparations for the treatment of neurodegenerative diseases, Alzheimer's disease, cardiovascular and cerebrovascular diseases, central nervous system, Parkinson's disease; Pharmaceutical products for the treatment of neurodegenerative diseases, Alzheimer's disease, cardiovascular and cerebrovascular diseases, central nervous system, Parkinson's disease; Pharmaceutical preparations for human use for the treatment of neurodegenerative diseases, Alzheimer's disease, cardiovascular and cerebrovascular diseases, central nervous system, Parkinson's disease; Pharmaceutical preparations for the treatment of Parkinson's disease; Pharmaceutical preparations for the treatment of Alzheimer's disease; Pharmaceutical preparations for the treatment of neurodegenerative diseases; Pharmaceutical preparations for the treatment of cerebral disease; Pharmaceutical preparations for the treatment of central nervous system diseases

Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; Consultancy relating to pharmaceutical research and development; Biological research, clinical research and medical research in the field of pharmaceuticals; Medical research laboratory services; Conducting technical tests on pharmaceuticals; Conducting analysis of human serum for medical research; Conducting analysis of human tissues for medical research; Development of pharmaceutical preparations and medicines; Pharmaceutical products development; Research and development of vaccines and medicines; Providing scientific information in the field of medical disorders and their treatment; Research in the field of pharmacogenetics; Research relating to pharmaceuticals; Research and development in the field of pharmacy and biotechnology; Clinical research in the field of pharmaceuticals; Laboratory research services relating to pharmaceuticals; Medical research; Medical and pharmacological research services; Pharmaceutical drug development services; Pharmaceutical research services; Pharmaceutical research and development; Quality testing for pharmaceutical products; Scientific research in the field of pharmacy; Scientific research and development

Filing History

NOTICE OF REGISTRATION CONFIRMATION EMAILED
Dec 24, 2024 NRCC
REGISTERED-PRINCIPAL REGISTER
Dec 24, 2024 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Oct 22, 2024 NPUB
PUBLISHED FOR OPPOSITION
Oct 22, 2024 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Oct 2, 2024 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Sep 13, 2024 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Aug 11, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Aug 11, 2024 CRFA
ASSIGNED TO LIE
Aug 10, 2024 ALIE
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Mar 25, 2024 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Mar 25, 2024 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Mar 25, 2024 REAP
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Feb 23, 2024 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Dec 7, 2023 GNRN
NON-FINAL ACTION E-MAILED
Dec 7, 2023 GNRT
NON-FINAL ACTION WRITTEN
Dec 7, 2023 CNRT
ASSIGNED TO EXAMINER
Dec 6, 2023 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Mar 28, 2023 NWOS
NEW APPLICATION ENTERED
Mar 11, 2023 NWAP